{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:54:56Z","timestamp":1790751296386,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctro.2026.101264","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:10:50Z","timestamp":1786947050000},"page":"101264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["European lung cancer congress 2026 \u2013 the thoracic radiation oncologist's view."],"prefix":"10.1016","volume":"61","author":[{"given":"Franz","family":"Zehentmayr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rimner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"El-Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"P\u00f6ttgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Guberina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Guberina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9962","key":"10.1016\/j.ctro.2026.101264_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ctro.2026.101264_bb0010","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctro.2026.101264_bb0015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2025.06.3872","article-title":"Low-dose radiation therapy concurrent with atezolizumab and chemotherapy as first-line treatment for extensive-stage small cell lung Cancer: 3-year follow-up of a Multicenter, single-arm, phase 2 trial (MATCH)","volume":"124","author":"Zhou","year":"2026","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"23","key":"10.1016\/j.ctro.2026.101264_bb0020","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.ctro.2026.101264_bb0025","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctro.2026.101264_bb0030","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line Serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung Cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ctro.2026.101264_bb0035","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a Multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"10495","key":"10.1016\/j.ctro.2026.101264_bb0040","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctro.2026.101264_bb0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung Cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctro.2026.101264_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctro.2026.101264_bb0055","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","article-title":"Radiation therapy for small cell lung Cancer: an ASTRO clinical practice guideline","volume":"10","author":"Simone","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.ctro.2026.101264_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1929","article-title":"Rates of overall survival and intracranial control in the magnetic resonance imaging era for patients with limited-stage small cell lung Cancer with and without prophylactic cranial irradiation","volume":"3","author":"Pezzi","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.ctro.2026.101264_bb0065","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1016\/j.ijrobp.2023.08.031","article-title":"Stereotactic radiotherapy vs. whole brain radiation therapy for patients with 1-10 brain metastases from small cell lung cancer: results of the randomized ENCEPHALON (ARO 2018-9) trial","volume":"117","author":"Bernhardt","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.ctro.2026.101264_bb0070","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Zer","year":"2025","journal-title":"Ann. Oncol."},{"issue":"21","key":"10.1016\/j.ctro.2026.101264_bb0075","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in Resectable lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ctro.2026.101264_bb0080","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.ctro.2026.101264_bb0085","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for Resectable non-small-cell lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ctro.2026.101264_bb0090","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in Resectable lung Cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctro.2026.101264_bb0095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative Toripalimab plus chemotherapy for patients with Resectable non-small cell lung Cancer: the Neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ctro.2026.101264_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70081","article-title":"Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: predictors of surgery, pathologic complete response, and event-free survival","volume":"131","author":"Cooper","year":"2025","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ctro.2026.101264_bb0105","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung Cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"29","key":"10.1016\/j.ctro.2026.101264_bb0110","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with Oleclumab or Monalizumab in patients with unresectable, stage III non-small-cell lung Cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctro.2026.101264_bb0115","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamaoncol.2024.1897","article-title":"Atezolizumab before and after chemoradiation for unresectable stage III non-small cell lung Cancer: a phase II nonrandomized controlled trial","volume":"10","author":"Ross","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2026.101264_bb0120","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.23.00627","article-title":"Selective personalized RadioImmunotherapy for locally advanced non-small-cell lung Cancer trial (SPRINT)","volume":"42","author":"Ohri","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctro.2026.101264_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(25)00756-9","article-title":"Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment","volume":"27","author":"De Ruysscher","year":"2026","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.ctro.2026.101264_bb0130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctro.2026.101264_bb0135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ctro.2026.101264_bb0140","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jtho.2023.04.008","article-title":"Korean real-world data on patients with unresectable stage III NSCLC treated with durvalumab after chemoradiotherapy: PACIFIC-KR","volume":"18","author":"Park","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctro.2026.101264_bb0145","doi-asserted-by":"crossref","first-page":"S939","DOI":"10.1016\/j.annonc.2021.08.1775","article-title":"PACIFIC-R real-world study: treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy","volume":"32","author":"Girard","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ctro.2026.101264_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"Esmo Open"},{"key":"10.1016\/j.ctro.2026.101264_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110294","volume":"196","author":"Zehentmayr","year":"2024","journal-title":"Radiother. Oncol."},{"issue":"9","key":"10.1016\/j.ctro.2026.101264_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17091443","article-title":"Durvalumab prolongs overall survival, whereas radiation dose escalation > 66 Gy might improve long-term local control in unresectable NSCLC stage III: updated analysis of the Austrian radio-oncological lung Cancer study association registry (ALLSTAR)","volume":"17","author":"Zehentmayr","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctro.2026.101264_bb0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2025.09.008","article-title":"ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors","volume":"37","author":"van Aken","year":"2026","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ctro.2026.101264_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106076","article-title":"ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF\/MEK inhibitors","volume":"11","author":"van Aken","year":"2026","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ctro.2026.101264_bb0175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijrobp.2023.09.009","article-title":"Treatment-related pneumonitis of EGFR tyrosine kinase inhibitors plus thoracic radiation therapy in patients with non-small cell lung Cancer: a systematic review and Meta-analysis","volume":"118","author":"Meng","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ctro.2026.101264_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100892","article-title":"Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis - the challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging","volume":"39","author":"Guberina","year":"2023","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.ctro.2026.101264_bb0185","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.clon.2020.02.003","article-title":"The UK at the forefront of innovative drug-radiotherapy combination clinical trials: introducing the CONCORDE platform","volume":"32","author":"Faivre-Finn","year":"2020","journal-title":"Clin. Oncol. (R Coll Radiol)"},{"key":"10.1016\/j.ctro.2026.101264_bb0190","doi-asserted-by":"crossref","first-page":"e2200133","DOI":"10.1200\/PO.22.00133","article-title":"Implementation of the time-to-event continuous reassessment method design in a phase I platform trial testing novel radiotherapy-drug combinations-CONCORDE","volume":"6","author":"Walker","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctro.2026.101264_bb0195","first-page":"61","article-title":"CONCORDE: a phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer","volume":"25","author":"Walls","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101264_bb0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.radonc.2003.09.007","article-title":"Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer","volume":"71","author":"Senan","year":"2004","journal-title":"Radiother. Oncol."},{"issue":"16_Suppl","key":"10.1016\/j.ctro.2026.101264_bb0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8003","article-title":"SWOG\/NRG S1914: randomized phase III trial of induction\/consolidation atezolizumab plus SBRT versus SBRT alone in high risk, early-stage NSCLC","volume":"43","author":"Simone","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctro.2026.101264_bb0210","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung Cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ctro.2026.101264_bb0215","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","article-title":"Stereotactic ablative radiation for Oligoprogressive cancers: results of the randomized phase 2 STOP trial","volume":"121","author":"Schellenberg","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10422","key":"10.1016\/j.ctro.2026.101264_bb0220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2026.101264_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108553","article-title":"Multimodality treatment in synchronous oligometastatic NSCLC: analysis of the ETOP CHESS trial","volume":"204","author":"Guckenberger","year":"2025","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ctro.2026.101264_bb0230","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jtho.2016.06.011","article-title":"Postoperative radiation therapy is associated with longer overall survival in completely resected stage II and III thymoma-an analysis of the international thymic malignancies interest group retrospective database","volume":"11","author":"Rimner","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.ctro.2026.101264_bb0235","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jtho.2023.12.011","article-title":"Postoperative radiation therapy for thymic carcinoma: an analysis of the international thymic malignancy interest group\/European Society of Thoracic Surgeons database","volume":"19","author":"Rimner","year":"2024","journal-title":"J. Thorac. Oncol."}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082600159X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082600159X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:59:18Z","timestamp":1790747958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240563082600159X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":47,"alternative-id":["S240563082600159X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101264","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European lung cancer congress 2026 \u2013 the thoracic radiation oncologist's view.","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101264"}}